PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Save
405203 100 µg ¥10,500
405204 500 µg ¥36,960
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified

Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  2. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  3. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  4. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  5. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  6. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  7. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  8. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  9. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  10. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  11. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  12. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  13. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  14. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  15. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. Larsen SB, et al. 2021. Cell Stem Cell. :. PubMed
  18. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  19. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  20. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  21. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  22. Biswas S, et al. 2021. Nature. 591:464. PubMed
  23. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  24. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  25. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  26. Gniffke EP, et al. 2020. medRxiv. . PubMed
  27. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  28. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  29. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  30. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  31. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  32. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  33. Cao Y, et al. 2022. Nature. :. PubMed
  34. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  35. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  36. Im S, et al. 2016. Nature. 537:417-421. PubMed
  37. Schanda N, et al. 2021. Cells. 10:. PubMed
  38. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  39. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  40. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  41. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  42. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  43. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  44. Cao Y, et al. 2022. Nature. 602:657. PubMed
  45. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  46. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  47. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  48. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  49. Köchl R, et al. 2020. Elife. 9:00. PubMed
  50. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  51. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  52. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  53. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  54. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  55. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  56. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  57. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  58. Weiß S, et al. 2020. medRxiv. . PubMed
  59. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  60. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  61. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  62. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  63. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  64. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  65. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  66. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  67. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  68. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  69. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  70. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  71. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  72. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  73. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  74. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  75. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  76. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  77. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  78. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  79. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  80. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  81. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  82. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  83. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  84. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  85. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  86. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  87. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  88. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  89. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  90. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  91. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  92. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  93. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  94. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  95. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  96. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  97. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  98. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  99. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  100. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  101. Dan JM, et al. 2021. Science. :371. PubMed
  102. He X, et al. 2014. J Immunol. 193:1314. PubMed
  103. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  104. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  105. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  106. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  107. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  108. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  109. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  110. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  111. Wells DK, et al. 2020. Cell. 183:818. PubMed
  112. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  113. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  114. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  115. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  116. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  117. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  118. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  119. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  120. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  121. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  122. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  123. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  124. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  125. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  126. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  127. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  128. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  129. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  130. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  131. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  132. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06/17/2019

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account